Over the past two decades biologic therapies have seen a rapid uptake in the management of ocular inflammation. Peripheral ulcerative keratitis (PUK), once a harbinger of blindness and mortality in refractory rheumatological disease, is now increasingly being treated with these agents. We conducted a review to evaluate the evidence base for this application and to provide a road map for their clinical usage in PUK, including dosage and adverse effects. A literature search across Medline, Embase and Cochrane Database of Systematic Reviews was undertaken to identify all patients with PUK that were treated with a biologic in a peer viewed article. Overall, whilst the evidence base for biologic use in PUK was poor, reported cases demonstrate an increasingly powerful and effective role for biologics in refractory PUK. This was particularly the case for rituximab in PUK secondary to granulomatous with polyangiitis.
Competing Interests: Declaration of Competing Interest We declare this manuscript is original, has not been published before and is not being considered for publication elsewhere. We know of no conflicts of interest associated with the publication, and there has been no significant financial support for this work that could have influenced its outcome. I can confirm that the manuscript has been read and approved for submission by all the named authors.
(Copyright © 2023. Published by Elsevier Inc.)